Johnson & Johnson psoriasis drug ustekinumab (also called Stelara) gave better results than Enbrel, now a leading drug for psoriasis, a new study has found. The study by Johnson & Johnson's biotech unit, Centocor Inc., will give the company more market share in the treatment of psoriasis, a painful skin condition.

Enbrel, an equally safe drug which is jointly marketed by Wyeth and Amgen, currently commands 75 percent of the global market. The study was the first to help Johnson & Johnson's psoriasis treatment challenge that of Enbrel

Embryonic stem cell-derived cells can help prevent rejection of hearts transplanted into mice without the use of immunosuppressive drugs, researchers say.

The implications are huge for people who have undergone bone marrow or organ transplants and must take drugs that suppress their immune systems to avoid having their bodies reject the transplanted organ as foreign tissue

An experimental new breast cancer vaccine has completely eliminated a type of breast cancer tumour in tests on mice, say researchers.

The vaccine targets breast cancers that grow wildly in response to a growth factor called HER-2, which is prevalent in about 25 percent of women with breast cancer

Regular brushing of teeth can reduce your chances of developing heart disease, says a new study.

Researchers from the University of Bristol in Britain say that failing to scrub one's teeth can result in the formation of up to 700 different bacteria in the human mouth that in turn can trigger heart disease

Four rheumatoid arthritis drugs have received stronger warnings from the U.S. Food and Drug Administration (FDA) after the drugs have been linked to deaths in 45 patients.

The FDA has received 240 reports of people taking the drugs Cimzia, Enbrel, Humira, and Remicade, which are called TNF blockers. All of then developed histoplasmosis, a fungal infection that starts as a respiratory infection and can spread throughout the body